New uses for new and old quinolones and the challenge of resistance.
Hooper
D C
DC
Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114-2696, USA. dhooper@partners.org
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000494:pharmacology*; D001424:Bacterial Infections / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000009:adverse effects / Q000494:pharmacology; D015242:Ofloxacin / Q000009:adverse effects / Q000494:pharmacology; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology; D012141:Respiratory Tract Infections / Q000188:drug therapy; D012680:Sensitivity and Specificity; D012749:Sexually Transmitted Diseases / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D010879:Piperazines; C080163:trovafloxacin; D015242:Ofloxacin; C075375:grepafloxacin; C061363:sparfloxacin